|
|
正清风痛宁治疗痛风性关节炎有效性及安全性的Meta分析
|
Abstract:
目的：系统评价正清风痛宁治疗痛风性关节炎(GA)的疗效。方法：计算机检索自建库至2024年8月1日相关数据库中有关正清风痛宁治疗痛风性关节炎的随机对照试验(RCT)。提取患者临床有效率、血尿酸水平、红细胞沉降率、C-反应蛋白和不良反应发生率进行统计学分析，系统评价正清风痛宁治疗痛风性关节炎的临床疗效及安全性。结果：本研究共纳入9篇RCT研究，包含582例患者(治疗组292，对照组290)。Meta分析结果显示：正清风痛宁在提高临床有效率(RR = 1.15, 95%CI [1.08, 1.23], Z = 4.23, P < 0.0001)、降低血尿酸(UA)水平(MD = ？28.16, 95%CI [？42.03, ？14.28], Z = 3.98, P < 0.0001)、降低血沉水平(MD = ？2.71, 95%CI [？3.63, ？1.80], Z = 5.82, P < 0.00001)等方面优于常规西医治疗，不良反应发生率无统计学差异(RR = 0.28, 95%CI [0.05, 1.59], Z = 1.44, P > 0.05)。结论：正清风痛宁相较于常规西医治疗可以提高对痛风性关节炎的临床疗效且具有良好的安全性。
Objective: To systematically evaluate the efficacy of Zhengqingfengtongning in treating gouty arthritis (GA). Methods: Randomized controlled trials (RCTs) on Zhengqingfengtongning for gouty arthritis were retrieved from relevant databases from their inception to August 1, 2024. Data on clinical response rate, serum uric acid (UA) levels, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and adverse event rates were extracted for statistical analysis. A systematic evaluation of the clinical efficacy and safety of Zhengqinfengtongning in treating gouty arthritis was conducted. Results: Nine RCTs involving 582 patients (292 in the treatment group, 290 in the control group) were included. Meta-analysis demonstrated that Zhengqingfengtongning was superior to conventional Western medicine in the following aspects: Clinical response rate RR = 1.15, 95% CI [1.08, 1.23], Z = 4.23, P < 0.0001, reduce blood uric acid (UA) level MD = ？28.16, 95%CI [？42.03, ？14.28], Z = 3.98, P < 0.0001, reduce blood sedimentation MD = ？2.71, 95%CI [？3.63, ？1.80], Z = 5.82, P < 0.00001, no statistically significant difference in the incidence of adverse reactions RR = 0.28, 95%CI [0.05, 1.59], Z = 1.44, P > 0.05. Conclusion: Zhengqingfengtongning can improve the clinical efficacy of gouty arthritis compared with conventional Western medical treatment, and it has a good safety profile.
| [1] | Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., et al. (2017) 2016 Updated EULAR Evidence-Based Recommendations for the Management of Gout. Annals of the Rheumatic Diseases, 76, 29-42. https://doi.org/10.1136/annrheumdis-2016-209707 |
| [2] | Sautner, J., Eichbauer-Sturm, G., Gruber, J., Lunzer, R. and Puchner, R. (2022) Empfehlungen der Österreichischen Gesellschaft für Rheumatologie und Rehabilitation zu Ernährung und Lebensstil bei Gicht und Hyperurikämie—Update 2022. Zeitschrift für Rheumatologie, 82, 71-81. https://doi.org/10.1007/s00393-022-01286-2 |
| [3] | Zhu, B., Wang, Y., Zhou, W., Jin, S., Shen, Z., Zhang, H., et al. (2022) Trend Dynamics of Gout Prevalence among the Chinese Population, 1990-2019: A Joinpoint and Age-Period-Cohort Analysis. Frontiers in Public Health, 10, Article 1008598. https://doi.org/10.3389/fpubh.2022.1008598 |
| [4] | 姜泉, 韩曼, 唐晓颇, 等. 痛风和高尿酸血症病证结合诊疗指南[J]. 中医杂志, 2021, 62(14): 1276-1288. |
| [5] | 郑筱萸. 中药新药临床研究指导原则第2辑[M]. 北京: 中国医药科技出版社, 2002: 179-183. |
| [6] | 庄治宁. 青藤碱预防痛风降尿酸过程中急性发作的临床疗效观察[D]: [硕士学位论文]. 天津: 天津中医药大学, 2023. |
| [7] | 汤冀, 杨正生, 曾宪茗, 等. 正清风痛宁经皮透药联合片剂治疗痛风性关节炎的临床研究[J]. 黑龙江中医药, 2023, 52(5): 41-43. |
| [8] | 刘瑶. 青藤碱定点介入治疗痛风性关节炎的临床效果观察[J]. 中外医学研究, 2021, 19(18): 55-57. |
| [9] | 侯新聚, 马红梅, 朱满华. 运用红外热像评价青藤碱定点介入治疗痛风性关节炎的临床疗效观察[J]. 临床医药实践, 2020, 29(8): 563-566. |
| [10] | 方菁, 熊辉, 陆小龙, 等. 蠲痹历节清方联合正清风痛宁经皮透药治疗急性痛风性关节炎30例[J]. 湖南中医杂志, 2018, 34(6): 62-64. |
| [11] | 赵玉娟, 蔡少峰, 时晶. 正清风痛宁经皮给药联合金黄散外敷治疗急性痛风性关节炎60例[J]. 河南中医, 2016, 36(8): 1437-1438. |
| [12] | 陈新, 毛兵, 车德亚, 等. 正清风痛宁注射液电致孔透皮给药治疗痛风性关节炎临床观察[J]. 中国中医急症, 2014, 23(4): 706-708. |
| [13] | 肖敬, 尹智功, 刘江, 等. 盐酸青藤碱注射液关节腔冲洗及注射治疗急性痛风性膝关节炎32例[J]. 中国中医药现代远程教育, 2013, 11(6): 9-10. |
| [14] | 程华威, 戴基浩, 董和平, 等. 清热活血逐痹汤联合正清风痛宁对痛风性关节炎的炎症反应及生活质量的影响[J]. 辽宁中医杂志, 2025(1): 55-58. |
| [15] | 陶弘景. 名医别录[M]. 尚志钧, 校. 北京: 人民卫生出版社, 1986: 38. |
| [16] | 佚名. 黄帝内经素问[M]. 王冰, 注. 戴铭, 张淑贤, 校. 南宁: 广西科学技术出版社, 2016: 70. |
| [17] | 张机. 金匮要略[M]. 北京: 人民卫生出版社, 2014: 58. |
| [18] | (明)李时珍. 本草纲目[M]. 武汉: 崇文书局, 2015. |
| [19] | 国家药典委员会. 《中国药典》一部[M]. 北京: 中国医药科技出版社, 2010. |
| [20] | (宋)苏颂. 本草图经[M]. 合肥: 安徽科学技术出版社, 1994. |
| [21] | Yang, H., Yin, P., Shi, Z., Ma, Y., Zhao, C., Zheng, J., et al. (2015) Sinomenine, a COX-2 Inhibitor, Induces Cell Cycle Arrest and Inhibits Growth of Human Colon Carcinoma Cells in Vitro and in Vivo. Oncology Letters, 11, 411-418. https://doi.org/10.3892/ol.2015.3838 |
| [22] | 王文君, 王培训, 李晓娟. 青藤碱抗炎机理——青藤碱对人外周血单个核细胞环氧化酶活性及其基因表达的影响[J]. 中国中药杂志, 2003, 49(4): 67-70. |
| [23] | Li, J., Deng, H., Yao, Y., Wang, W., Hu, J., Dong, Y., et al. (2023) Sinomenine Ameliorates Collagen-Induced Arthritis in Mice by Targeting GBP5 and Regulating the P2X7 Receptor to Suppress NLRP3-Related Signaling Pathways. Acta Pharmacologica Sinica, 44, 2504-2524. https://doi.org/10.1038/s41401-023-01124-4 |
| [24] | Zeng, M. and Tong, Q. (2020) Anti-Inflammation Effects of Sinomenine on Macrophages through Suppressing Activated TLR4/NF-κB Signaling Pathway. Current Medical Science, 40, 130-137. https://doi.org/10.1007/s11596-020-2156-6 |
| [25] | Wang, X., Liu, Y., Zhang, H., Jin, J., Ma, Y. and Leng, Y. (2021) Sinomenine Alleviates Dorsal Root Ganglia Inflammation to Inhibit Neuropathic Pain via the P38 MAPK/CREB Signalling Pathway. European Journal of Pharmacology, 897, Article 173945. https://doi.org/10.1016/j.ejphar.2021.173945 |
